[Venovenous extracorporeal membrane oxygenation for COVID-19].
Venovenöse extrakorporale Membranoxygenierung bei COVID-19: Erkenntnisse eines Zentrums aus 96 konsekutiven Fällen.
ARDS
ECMO
Pandemic
Pneumonia
SARS-CoV‑2
Venovenous
Journal
Zeitschrift fur Herz-, Thorax- und Gefasschirurgie
ISSN: 0930-9225
Titre abrégé: Z Herz Thorax Gefasschir
Pays: Germany
ID NLM: 9112161
Informations de publication
Date de publication:
2022
2022
Historique:
received:
29
01
2022
revised:
17
02
2022
accepted:
17
02
2022
pubmed:
26
7
2022
medline:
26
7
2022
entrez:
25
7
2022
Statut:
ppublish
Résumé
Since the beginning of the COVID-19 pandemic global health systems are confronted with a large number of unknown problems. Venovenous (vv) extracorporeal membrane oxygenation (ECMO) in cases of therapy refractive ARDS often represents a last resort treatment. To improve the health care it is necessary to identify possible influencing factors. This analysis presents the findings of an ECMO centre and aims to identify potential factors with an impact on vv-ECMO therapy in cases of COVID-19. Between 03/2020 and 01/2022 Overall The use of vv-ECMO in cases of therapy resistant ARDS in COVID-19 still correlates with a high mortality and as such should only be considered as a last resort of intensive care treatment.According to our expectations we could notice better therapy results for younger patients as well as for women in our patient database. In addition, for most comorbidities we could not prove any negative influence on the therapy outcome. This knowledge could help to identify future high-risk patients.
Sections du résumé
Background
UNASSIGNED
Since the beginning of the COVID-19 pandemic global health systems are confronted with a large number of unknown problems. Venovenous (vv) extracorporeal membrane oxygenation (ECMO) in cases of therapy refractive ARDS often represents a last resort treatment. To improve the health care it is necessary to identify possible influencing factors.
Objective
UNASSIGNED
This analysis presents the findings of an ECMO centre and aims to identify potential factors with an impact on vv-ECMO therapy in cases of COVID-19.
Material and methods
UNASSIGNED
Between 03/2020 and 01/2022
Results
UNASSIGNED
Overall
Conclusion
UNASSIGNED
The use of vv-ECMO in cases of therapy resistant ARDS in COVID-19 still correlates with a high mortality and as such should only be considered as a last resort of intensive care treatment.According to our expectations we could notice better therapy results for younger patients as well as for women in our patient database. In addition, for most comorbidities we could not prove any negative influence on the therapy outcome. This knowledge could help to identify future high-risk patients.
Identifiants
pubmed: 35875598
doi: 10.1007/s00398-022-00528-4
pii: 528
pmc: PMC9295356
doi:
Types de publication
English Abstract
Journal Article
Review
Langues
ger
Pagination
323-327Informations de copyright
© The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2022.
Références
PLoS One. 2021 Dec 7;16(12):e0260324
pubmed: 34874960
Respir Med. 2020 Aug - Sep;170:106036
pubmed: 32469732
BMJ. 2020 May 22;369:m1966
pubmed: 32444366
Int J Mol Med. 2021 Jan;47(1):3-22
pubmed: 33236131
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013 May;56(5-6):786-94
pubmed: 23703499
J Thorac Dis. 2019 Sep;11(Suppl 14):S1698-S1707
pubmed: 31632747
EClinicalMedicine. 2020 Nov;28:100579
pubmed: 33073217
Respir Med. 2021 Jan;176:106237
pubmed: 33246296
Am J Respir Crit Care Med. 2021 Oct 15;204(8):991-994
pubmed: 34283685
Crit Care. 2021 Nov 29;25(1):413
pubmed: 34844657
J Hepatol. 2021 Jan;74(1):168-184
pubmed: 33038433
Lancet. 2021 Oct 2;398(10307):1230-1238
pubmed: 34599878
Crit Care. 2020 Aug 17;24(1):507
pubmed: 32807189
World J Virol. 2021 Jan 25;10(1):1-29
pubmed: 33585175
ASAIO J. 2021 May 1;67(5):485-495
pubmed: 33657573
Front Public Health. 2020 Apr 29;8:152
pubmed: 32411652